Literature DB >> 10784613

Tumor angiogenesis factors reduce leukocyte adhesion in vivo.

S C Tromp1, M G oude Egbrink, R P Dings, S van Velzen, D W Slaaf, H F Hillen, G J Tangelder, R S Reneman, A W Griffioen.   

Abstract

Leukocyte-endothelium interactions are diminished in tumors. It is reported here that, in a tumor-free in vivo model, angiogenic factors can down-regulate leukocyte adhesion to endothelium. Slow releasing pellets were loaded with either basic fibroblast growth factor (bFGF), vascular endothelial cell growth factor (VEGF) or vehicle alone and were placed in the scrotum of mice. After 3 days, a single intrascrotal injection of 1 microg/kg IL-1beta was given 4 h before vessels of the cremaster muscle were investigated for leukocyte rolling and adhesion by means of intravital microscopy. Exposure of normal tissue to either bFGF or VEGF resulted in markedly decreased levels of cytokine-induced leukocyte adhesion. Suppression of leukocyte rolling was not observed. Instead a moderate enhancement of rolling by VEGF was found. The observed differences could not be explained by differences in fluid dynamic parameters or systemic leukocyte counts. In conclusion, evidence is presented that, in vivo, angiogenic factors significantly reduce leukocyte adhesion, the final step preceding leukocyte infiltration. This observation may explain why tumors escape from immune surveillance.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10784613     DOI: 10.1093/intimm/12.5.671

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  23 in total

1.  Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma.

Authors:  Lin Zhang; Nuo Yang; Jose-Ramon Conejo Garcia; Alisha Mohamed; Fabian Benencia; Stephen C Rubin; David Allman; George Coukos
Journal:  Am J Pathol       Date:  2002-12       Impact factor: 4.307

2.  Targeted transcriptional profiling of the tumor microenvironment reveals lymphocyte exclusion and vascular dysfunction in metastatic osteosarcoma.

Authors:  Laurie Sorenson; Yanfen Fu; Tressa Hood; Sarah Warren; Troy A McEachron
Journal:  Oncoimmunology       Date:  2019-06-27       Impact factor: 8.110

Review 3.  Anti-angiogenic agents - overcoming tumour endothelial cell anergy and improving immunotherapy outcomes.

Authors:  Zowi R Huinen; Elisabeth J M Huijbers; Judy R van Beijnum; Patrycja Nowak-Sliwinska; Arjan W Griffioen
Journal:  Nat Rev Clin Oncol       Date:  2021-04-08       Impact factor: 66.675

Review 4.  Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa.

Authors:  Kabir A Khan; Robert S Kerbel
Journal:  Nat Rev Clin Oncol       Date:  2018-02-13       Impact factor: 66.675

5.  Basic fibroblast growth factor (bFGF, FGF-2) potentiates leukocyte recruitment to inflammation by enhancing endothelial adhesion molecule expression.

Authors:  Sandra I Zittermann; Andrew C Issekutz
Journal:  Am J Pathol       Date:  2006-03       Impact factor: 4.307

6.  Enhancement of T-cell-mediated antitumor response: angiostatic adjuvant to immunotherapy against cancer.

Authors:  Ruud P M Dings; Kieng B Vang; Karolien Castermans; Flavia Popescu; Yan Zhang; Mirjam G A Oude Egbrink; Matthew F Mescher; Michael A Farrar; Arjan W Griffioen; Kevin H Mayo
Journal:  Clin Cancer Res       Date:  2011-01-20       Impact factor: 12.531

7.  Basic fibroblast growth factor alleviates brain injury following global ischemia reperfusion in rabbits.

Authors:  Mao Zhang; Yue-feng Ma; Jian-xin Gan; Guan-yu Jiang; Shan-xiang Xu; Xiang-luo Tao; An Hong; Jiao-kun Li
Journal:  J Zhejiang Univ Sci B       Date:  2005-07       Impact factor: 3.066

8.  Immune escape mechanism: defective resting and stimulated leukocyte-endothelium interaction in hepatocellular carcinoma of the rat.

Authors:  Sasa-Marcel Maksan; Patrick Morad Araib; Eduard Ryschich; Martha Maria Gebhard; Jan Schmidt
Journal:  Dig Dis Sci       Date:  2004-05       Impact factor: 3.199

9.  Anti-VEGF single-chain antibody GLAF-1 encoded by oncolytic vaccinia virus significantly enhances antitumor therapy.

Authors:  Alexa Frentzen; Yong A Yu; Nanhai Chen; Qian Zhang; Stephanie Weibel; Viktoria Raab; Aladar A Szalay
Journal:  Proc Natl Acad Sci U S A       Date:  2009-07-15       Impact factor: 11.205

10.  Minute dosages of alpha(nu)beta3-targeted fumagillin nanoparticles impair Vx-2 tumor angiogenesis and development in rabbits.

Authors:  Patrick M Winter; Anne H Schmieder; Shelton D Caruthers; Jeffery L Keene; Huiying Zhang; Samuel A Wickline; Gregory M Lanza
Journal:  FASEB J       Date:  2008-03-24       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.